The FDA announced regulatory actions to accelerate development of psychedelic medications for serious mental illness, following a presidential executive order.
← News
Medicine Breakthroughs Medicine Breakthroughs Health
FDA Accelerates Action on Treatments for Serious Mental Illness Following Executive Order | HHS.gov
Serotonin-2A Agonists Drug class targeted
Serious And Treatment-Resistant Mental Illness Focus population
Presidential Executive Order, April 18 Policy driver